Pitvarfibrilláció: ki dolgozik rajta

Intézményenként egy kártya. Válassz célpontot, és csak az azon dolgozó csoportok maradnak.

• Minden célpont
• GLP-1 5
• SGLT2 5
• NLRP3 0
• BTK 3
• AMPK 0
• PI3K 0
• GIP 3
• PPAR 0
• TTR 0
• AKT 0
• PCSK9 0
• STAT3 0
• BDNF 1
• COX-2 0
• ERK 0
• HMGB1 0
• HSP90 0
• IL-6 0
• METTL3 0
• NRF2 0
• PD-1 0
• PD-L1 0
• TP53 0
• VEGF 0
• ABL1 0
• ALK 0
• ANGPTL3 0
• APOE 0
• CD40 0
• CDK4/6 0
• CFTR 0
• EGFR 0
• FTO 0
• HER3 0
• HIF-1 0
• IGF1R 0
• RUNX1 0
• SIRT1 0
• STING 0
• STK11 0
• TLR4 0
• TNF 0
• TREM2 0
• YAP 0

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Integrative Modeling of Autonomic dysfunction and Cardiac arrhyThmogenesis (IMpACT)

  Politecnico di Milano· Milano, Olaszország· EU contribution 193 643 EUR· until 2029. aug.· 3 countries

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Molecular, cellular, and pharmacological characterization of a new modality of familial arrhythmia (Na-CPVT)

  Linkopings Universitet· Linkoping, Svédország· EU contribution 252 180 EUR· until 2029. jan.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Holistic Efficient Arrhythmic Risk Twinning for Post-MI Stratification (HEART-TWIN)

  Universidad Pompeu Fabra· Barcelona, Spanyolország· EU contribution 209 915 EUR· until 2028. dec.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  A computational framework for personalising atrial fibrillation treatment to minimise heart failure risk (AFHF-TAILOR)

  Eidgenoessische Technische Hochschule Zuerich· Zuerich, Svájc· EU contribution 292 119 EUR· until 2028. dec.· 2 countries

• European Commission (Horizon Europe) · HORIZON-ERC

  Advanced Tissue Engineering, Bioprinting, and 5D Optogenetics for Arrhythmia Investigation and Treatment (OptoPrintRhythm)

  Technion - Israel Institute of Technology· Haifa, Izrael· EU contribution 3 375 000 EUR· until 2031. dec.

• European Commission (Horizon Europe) · HORIZON-ERC

  Topology for understanding the paired nature of cardiac arrhythmia (TOPOHEART)

  Universiteit Gent· Gent, Belgium· EU contribution 2 000 000 EUR· until 2031. dec.

• European Commission (Horizon Europe) · HORIZON-ERC

  Switching cardiomyocyte activity to uncover biology and treat disease. (CARDIOSWITCH)

  Centro Nacional de Investigaciones Cardiovasculares Carlos Iii (F.s.p.)· Madrid, Spanyolország· EU contribution 2 428 125 EUR· until 2031. okt.

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Unveiling Dynamic Autonomic Regulation in health and disease through Network Physiology (DARNePh)

  Univerzita Komenskeho V Bratislave· Bratislava 1, Szlovákia· EU contribution 172 942 EUR· until 2028. aug.· 2 countries

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-EIC

  HUMAN-BASED ADVANCED CARDIAC SAFETY PLATFORM INTEGRATING MULTILAYER CARDIAC ORGANOIDS, MESH MEA, AND AI-BASED PROARRHYTHMIA RISK ASSESSMENT (HEARTCORE)

  Medizinische Hochschule Hannover· Hannover, Németország· EU contribution 2 993 436 EUR· until 2030. máj.· 3 countries

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  towards virtual risk assessment for patient-specific stratification in Brugada syndrome (Br-TRAP)

  Medizinische Universitat Graz· Graz, Ausztria· EU contribution 214 345 EUR· until 2028. ápr.· 2 countries

  The disease is named only in the funder's project summary, not in the title.

10 of 43 running projects, newest first. Listed amounts together: 148,3 M EUR.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Vizsgálatok, amelyek regiszteradata szerint az egyéni résztvevői adatokat (IPD) megosztják.

Ebben a nézetben egy vizsgálat sem jelzi, hogy megosztaná a résztvevői adatokat.

Publikációk erről a betegségről egy MeSH-módszerkifejezés szerint, például szekvenálási vagy képalkotó módszerre.

• Single-Cell Analysis 5
• Organoids 1
• Mendelian Randomization Analysis 75
• Gene Expression Profiling 31
• Whole Genome Sequencing 1
• Exome Sequencing 3
• Proteomics 16
• Metabolomics 14
• Mass Spectrometry 3
• Flow Cytometry 2
• Immunohistochemistry 2
• Positron-Emission Tomography 1
• Magnetic Resonance Imaging 67
• Machine Learning 88
• Deep Learning 35
• Cohort Studies 220
• Genome-Wide Association Study 62

• Divergent mitochondrial and fibrotic signatures in atrial fibrillation: insights from organoids and GEO data.

  Cardiovasc Diabetol, 2026. júl.

Megmutatjuk, a betegség mely célpontjait említi az absztrakt, és onnan a rajtuk dolgozókhoz jutsz.